Health ❯Pharmaceuticals ❯Vaccines

Respiratory Vaccines

Icosavax AstraZeneca IVX-A12 RSV and hMPV Virus-like Particles

AstraZeneca to Acquire Icosavax for $1.1 Billion

Deal includes access to experimental vaccines targeting respiratory diseases, with closing expected in Q1 2024.